HL Genomics will make its debut on the KOSDAQ market on the 23rd. It is a pharmaceutical company that researches, develops, manufactures, processes, stores, and distributes active pharmaceutical ingredients (APIs), producing APIs for prescription drugs in accordance with the Pharmacists Act.

Investors are closely watching the stock price movement on the first day of listing. HL Genomics conducted a public subscription for general investors through KB Securities and IBK Investment Securities from the 13th to the 14th.

As of 4 p.m. on the 14th, the last day of subscription, 184,971 applications were received through KB Securities and 22,458 through IBK Investment Securities. Based on the minimum subscription requirement, the equal allocation shares were 1.56 shares at KB Securities and 1.43 shares at IBK Investment Securities. The proportional competition rates were recorded at 1,364.26 to 1 for KB Securities and 1,057.14 to 1 for IBK Investment Securities.

The market is paying close attention to the stock price movement on the first day of listing compared to the IPO price. Given the ongoing cases of expanding volatility among newly listed stocks, the stock price trend will be worth monitoring.

[This article is not intended to solicit investment. The final judgment and responsibility for all investments lie with the investor.]